Advisory Board: Bios
George Daley, MD, PhD Venture Partner, Chief Medical/Scientific Advisor
George Q. Daley, M.D., Ph.D. is the Samuel E. Lux IV Professor of Hematology/Oncology and the Director of the Stem Cell Transplantation Program at Children's Hospital Boston. He is also Professor in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, an investigator of the Howard Hughes Medical Institute, Associate Director of Children's Stem Cell Program, a member of the Executive Committee of the Harvard Stem Cell Institute, and past-President of the International Society for Stem Cell Research (2007-2008). Dr. Daley's research is aimed at translating insights in stem cell biology into improved therapies for genetic diseases. Important research contributions from his laboratory include the use of nuclear transfer to create customized stem cells to treat genetic immune deficiency in a mouse model (together with Rudolf Jaenisch), the creation of germ cells from embryonic stem cells, and the generation of disease-specific pluripotent stem cells by direct reprogramming of human fibroblasts, work that was cited as the "Breakthrough of the Year" for 2008 by Science magazine. As a graduate student working with Nobelist Dr. David Baltimore, Dr. Daley proved that the BCR/ABL oncogene causes human chronic myeloid leukemia (CML), which validated BCR/ABL as a target for drug blockade and encouraged the development of imatinib (GleevecTM; Novartis), a revolutionary magic-bullet chemotherapy that induces remissions in virtually every CML patient. Dr. Daley's recent studies have clarified mechanisms of Gleevec resistance and have helped identify novel combination chemotherapeutic regimens.
Dr. Daley received his bachelor's degree magna cum laude from Harvard University (1982), a Ph.D. in biology from MIT (1989), and the M.D. from Harvard Medical School, where he was only the twelfth individual in the school's history to be awarded the degree summa cum laude (1991). He served as Chief Resident in Internal Medicine at the Massachusetts General Hospital and is currently a staff physician in Hematology/Oncology at the Children's Hospital, the Dana Farber Cancer Institute, and the Brigham and Women's Hospital in Boston. He has been elected a fellow of the American Association for the Advancement of Science and a member of the American Society for Clinical Investigation and American Pediatric Societies. Dr. Daley was an inaugural winner of the NIH Director's Pioneer Award, which provides a five year unrestricted grant to pursue highly innovative research, and was awarded the Judson Daland Prize from the American Philosophical Society for achievement in patient-oriented research and the E. Mead Johnson Award from the American Pediatric Society for contributions to stem cell research. In addition, he has received awards from the New England Cancer Society, the Burroughs Wellcome Fund, the Edward Mallinckrodt, Jr. Foundation, Harvard Medical School, and the Leukemia and Lymphoma Society of America.
Dr. Daley has been active in the biotechnology industry as a scientific advisor to companies and investors across the spectrum from start-ups to major pharma. He is currently a member of the Scientific Advisory Boards of MPM Capital, Epizyme Pharmaceuticals, Solasia, iPierian, Verastem, and Johnson+Johnson.